Sunday 18 October 2026
Export IRD’s income statement to Excel — free account
Opus Genetics, Inc.
Opus Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.2 million, up 29.1% from fiscal 2024. In the quarter to June 2026, revenue fell 73.8%, EPS grew 33.3% and free cash flow fell 16.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.81
0.24
−5.93%
Follow IRD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
39.82 | 32.99 | 8.81 | 7.96 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(32.84) | (31.06) | (12.72) | (18.93) | |
P/B ratio |
0.00 | 0.00 | 8.15 | 19.53 | |
Price to Tangible BV |
0.00 | 0.00 | 8.15 | 19.53 | |
EV/Sales |
34.37 | 28.10 | 5.72 | 5.95 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(8.33) | (8.64) | (2.30) | (2.65) | |
EV/FCF |
(8.02) | (8.30) | (2.21) | (2.53) | |
Quick Ratio |
11.82 | 6.60 | 6.05 | 1.16 | |
Current Ratio |
12.19 | 7.13 | 6.43 | 1.23 | |
Net Debt/EBITDA |
3.27 | 4.18 | 3.94 | 3.58 | |
Debt/Assets |
37.57% | 0.00% | 0.00% | 2.96% | |
Debt/Equity |
(2.69) | 0.00 | 0.00 | 0.18 | |
Asset Turnover |
0.15 | 0.21 | 0.33 | 0.38 | |
Operating CF/Net income |
1.48 | 0.19 | 0.60 | 0.35 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
— | (208.17) | (187.75) | (122.22) | |
Research and Development Expense of Revenue |
1,484.37% | 490.36% | 269.81% | 208.15% | |
Selling, General and Administrative Expense of Revenue |
798.41% | 275.57% | 126.52% | 161.77% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
186.36% | 67.87% | 20.03% | 26.50% | |
Graham Net Nets |
(0.03) | (0.12) | 0.12 | 0.05 | |
Graham Number |
1.99 | 3.97 | 0.00 | 0.00 | |
Earnings Yield |
(31.39%) | (29.23%) | (40.80%) | (113.94%) | |
Free Cash Flow Yield |
(10.77%) | (10.26%) | (29.46%) | (29.55%) | |
Revenue per Share |
0.01 | 0.02 | 0.06 | 0.04 | |
Operating CF per Share |
(0.13) | (0.15) | (0.16) | (0.09) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.13) | (0.15) | (0.16) | (0.09) | |
Cash per Share |
0.93 | 0.69 | 0.72 | 0.44 | |
Shareholders Equity per Share |
(0.14) | (0.53) | 0.25 | 0.08 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.14) | (0.53) | 0.25 | 0.08 | |
Free Cash Flow |
(11.95) | (12.73) | (9.83) | (6.16) | |
Working Capital |
85.09 | 57.26 | 42.26 | 6.82 | |
Net Current Asset Value |
(13.26) | (46.02) | 15.15 | 5.76 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.22 | 2.41 | 2.78 | 2.39 | |
Average Payables |
1.67 | 3.43 | 3.22 | 1.62 | |
Average Assets |
65.82 | 57.48 | 43.55 | 38.26 | |
Average Common Equity |
2.24 | (20.38) | 11.04 | 20.13 |
Columns are period end dates